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Abstract
Variability in response to drugs is a problem in clinical practice. The rate of patients who respond
adequately to pharmacological therapy is generally around 60. The CYP450 multienzyme complex is a
microsomal system located in the endoplasmic reticulum. The enzymes participate in phase I
metabolism of xenobiotics. CYP3A4 is the isoenzyme mostly expressed in liver. Its gene is polymorphic,
of which CYP3A4*1A is the wild allele and CYP3A4*2 is a polymorphism which consists of the S222P
substitution in the amino acid sequence, affecting the activity of the enzyme.
Methods: In this study, we determine the frequency of CYP3A4*2 polymorphism in Mexican
individuals. 62 apparently healthy individuals, from Toluca de Lerdo, Mexico. The sample was 3 mL of
peripheral blood. The DNA was extracted and PCR-RFLPs were performed.
Results: 58 individuals possess the wild allele in homozygosity CYP3A4*1A/CYP3A4*1A (94%) and 4
individuals were heterozygous CYP3A4*1A/CYP3A4*2 (6%). The homozygous polymorphic
CYP3A4*2/CYP3A4*2 was not found in any individual.
Conclusion: The CYP3A4*2 polymorphism is rare in the population studied. Given the low frequency of
CYP3A4*2 polymorphisms found in homozygous or heterozygous condition, it is advisable to consider
the genotype of the patient before prescribing drugs metabolized by this gene.
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Introduction
It is estimated that 99.9% of the DNA sequence of humans is
identical and the remaining 0.1% are genetic variations; these
are referred to as genetic polymorphisms. The study of these
polymorphisms has applications in the field of medicine, since
it is known that these variations in the DNA sequence that code
for enzymes, can alter their function [1,2].
Pharmacogenomics focuses on the identification of gene
variants that encode proteins that participate in the absorption,
distribution, metabolism and excretion of drugs. The response
to treatment depends not only on the age, gender and
physiological state of an individual, but also on their gene load.
This is relevant since it is estimated that most of the drugs
carry out their optimal therapeutic activity in 50% of the
patients who receive standard doses; the rest are under dosed or
overdosed and this results either in a lack of response to
treatment or in toxicity [3-5].
The cytochrome CYP450 multienzyme complex is a
microsomal system that is located in the endoplasmic reticulum
of the cell. Enzymes of this family are thiolase-type
monooxygenases and consist of hemoproteins in which iron
and NADH carry out oxidation, reduction, hydrolysis and
hydration reactions in phase I of xenobiotic metabolism to
produce polar compounds [6,7]. According to the similarity of
the peptides, the cytochrome P450 system is classified into 18
families and 44 subfamilies [8]. The most abundant families in
the liver are CYP3A, CYP1A2, CYP3A4, CYP2C, CYP2E1
and CYP2D6 [9].
CYP3A4 is the isoenzyme mostly expressed in the kidney,
intestine and liver. It reaches up to 50% of the total CYP3A
enzymes in the liver [8-10]. This gene is constitutive and is
located in chromosome 7 region 21.1. It has a length of 27 Kb.
It is composed of 12 introns and 13 exons, which encode the
enzyme classified as polypeptide 4 of subfamily IIIA [11,12].
It is a polymorphic gene with 78 described variants of which
CYP3A4*1A is the wild type allele and only the variants
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CYP3A4*1B, CYP3A4*2, CYP3A4*4, CYP3A4*5,
CYP3A4*18 and recently CYP3A4*22 are relevant, since
these affect the activity of the enzyme [8,11,13,14]. The
importance of the study of the CYP3A4 family lies in the fact
that it is the enzyme responsible for the metabolism of
approximately 50% of drugs, having as relevant substrates
cortisol, imatinib, testosterone, progesterone, benzo-a-pyrenes,
sterigmatocystin and aflatoxins, among others [10,11,15-17].
The CYP3A4*2 polymorphism consists of a substitution of a
thymine by a cytosine at position 673 (T673C) of exon 7 of the
nucleotide sequence of the gene, resulting in the change of a
serine (S) by a proline (P) at position 222 (S222P) in the amino
acid sequence. This change induces the formation of a turn in
the helix of the protein, resulting in quantitative differences in
the activity of the enzyme.
It has been reported that CYP3A4*2 participates in the
metabolism of Imatinib, a drug frequently used in the treatment
of patients with chronic myeloid leukemia. It can interfere with
the effectiveness of treatment [11-18].
At present, the growing knowledge of the molecular
mechanisms of health-disease processes is giving rise to the
clinical practice of a new personalized medication for each
individual, based on their gene load [19]. The presence or
absence of polymorphisms is very relevant to response to
treatment. Consequently, the objective of this study was to
know the frequency of the CYP3A4*2 polymorphism in
inhabitants of Toluca de Lerdo, Mexico, with the purpose of
being considered for a personalized prescription of treatment.
Materials and Methods
Study group
The investigation was of a transversal nature. It was carried out
in a group of apparently healthy students of the Autonomous
University of the State of Mexico. Participation was by
invitation and voluntary, those who accepted signed an
informed consent letter. A 3 mL sample of peripheral blood in
a Vacutainer tube with heparin was drawn from each
participant.
Ethical considerations
The authors agree that all the research was carried out in
compliance with government policies and the Declaration of
Helsinki (1964). This study was approved by the Research
Ethics Committee of the Medical Sciences Research Center of
the Universidad Autónoma del Estado de México.
DNA extraction
DNA extraction was performed from whole blood with the
Quick-gDNA Mini Prep Kit (Zymo Research). The DNA was
quantified using a NanoPhotometer (Implen). Additionally,
DNA quality and integrity were verified by horizontal
electrophoresis on 1% agarose.
Genotyping
The identification of the CYP3A4*2 polymorphism was
performed by PCR-RFLPs, according to Reyes et al., (2004),
which consists of the amplification of the region of interest by
endpoint PCR. The mixture had a final volume of 25 μL,
containing 5 μL 5x PCR Buffer (Promega), 4 μL of 25 mM
MgCl2 (Promega), 1 μL dNTPs Mix 10 mM (Fermentas), 10.7
μL of molecular biology grade H2O, 0.3 μL 5U/μL Taq
Polymerase (Promega), 2 μL of the DNA template and 1 μL of
the CYP3A4*2 primer. Forward: 5'-CCT GTT GCA TGC ATA
GAC-3 'and 1 μL of the CYP3A4*2 primer. Reverse: 5'-GAT
GAT GGT CAC ACA TAT C-3 ', both with a concentration of
30 pm/μL. The conditions used in this amplification were: 5
minutes at 95°C, denaturation 45 seconds at 95°C, alignment
45 seconds at 58°C, extension 45 seconds at 72°C and a final
elongation of 5 minutes at 72°C, for 35 cycles [18].
The PCR products were digested with restriction enzyme MnII.
The reaction mixture had a final volume of 20 μL, containing 7
μL molecular biology H2O, 2 μL 10X Buffer G (Thermo
Scientific), 1 μL of the enzyme MnII 5U/μL (Thermo
Scientific) and 10 μL DNA product of PCR. The reaction was
incubated at 37°C for 12 hours and inactivated at 65°C for 15
minutes. Digestion products were verified by horizontal
electrophoresis, in 1.5% agarose.
The identification of the polymorphism was based on the
presence of DNA fragments of different sizes. A 357bp
fragment corresponds to the wild-type allele CYP3A4*1A/
CYP3A4*1A (T/T). A 213 bp fragment and a 144 bp fragment
correspond to a heterozygous allele CYP3A4*1A/CYP3A4*2
(T/C). While the presence of a single 213 bp fragment
corresponds to the polymorphism in homozygous condition
CYP3A4*2/CYP3A4*2 (C/C). Additionally, a 9 bp product




The study group consisted of 62 apparently healthy
individuals, originally from Toluca de Lerdo, Mexico, of which
42 individuals (67.7%) were women and 20 individuals
(32.3%) were men. In an age range of 18 to 30 years.
Genotyping
The allelic frequencies of the study group were as follows: 58
individuals possess the wild-type allele CYP3A4*1A/
CYP3A4*1A (T/T), which represents 94%. Four individuals
possess the heterozygous allele CYP3A4*1A/CYP3A4*2
(T/C), meaning a 6%. While the homozygous polymorphic
CYP3A4*2/CYP3A4*2 (C/C) allele was not identified in any
individual of the study group. Detail of the data is presented in
Table 1.
Angélica/Fernando/Maricela/Laura/Julieta
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Discussion
Like other populations in the world, Mexicans constitute a
mestizo population, made up of ancestral Amerindian and
European origins, and in a smaller proportion of Africans [20].
CYP3A4 is the most important drug metabolizing enzyme in
humans, due to its prominent expression in the liver and
intestine and its broad substrate specificity, which includes
drugs from most therapeutic categories and many endogenous
substances [20,21].




CYP3A4*1A/CYP3A4*1A (T/T) 58 94
CYP3A4*1A/CYP3A4*2 (T/C) 4 6
CYP3A4*2/CYP3A4*2 (C/C) 0 0
Reyes et al. (2004), studied 69 individuals from Mexico. They
found only the wild allele (T/T) [10]. While Reyes et al.
(2008), reported the frequency of CYP3A4*2 in a population
of northern Mexico, where they only identified one individual
with the heterozygous allele (T/C) and the rest with the wild
version (T/T) [14]. Merging the previous data with the results
of this research, the average frequency of this polymorphism is
<3%. Regarding the distribution of the CYP3A4*2
polymorphism in other regions of the world, similar results are
reported. Sata et al. (2000), determined the frequency of this
polymorphism in 162 individuals from three different ethnic
groups, namely Caucasian from Finland, African-American
and Chinese. They found only 2.7% of the heterozygous allele
in the first group and 0% in the two remaining groups [18].
While Garsa et al. (2005), when studying two ethnic groups,
the first conformed by 95 European individuals and the second
one by 95 Africans found in both groups a frequency of 0% for
the CYP3A4*2 polymorphism [22]. In this same line, Cavaco
et al. (2013), conducted the study of 100 individuals from the
south of Portugal and reported a frequency of 4.5% for the
heterozygous allele (T/C) [23]. The results of the CYP3A4*2
polymorphism frequency reported here are similar to those
reported in other populations. They are relevant in terms of
their application to a pharmacogenomic approach.
The study of polymorphisms of CYP450 genes is relevant in
the area of health. Particularly the CYP3A4 gene is important
for high participation in the metabolism of antineoplastic drugs
(vinblastine, imatinib, paclitaxel, sterigmatocystin,
cyclophosphamide, doxorubicin, etoposide),
immunosuppressants (ciclosporin), hormones (cortisol,
testosterone, progesterone) and other xenobiotics (benzo-a-
pyrene and aflatoxins) [10,11,15,17,24-26]. In addition to this,
it has been determined that the CYP3A4*2 polymorphism
affects the activity of the enzyme [18], used nifedipine as a
substrate. They analyzed the enzymatic activity of the protein
encoded by CYP3A4*2, their results showed a 7.5-fold
decrease in the metabolism activity with this substrate. This
decrease in enzymatic activity is important, since it can
influence the metabolism of a large number of xenobiotics and
drugs, resulting in an increase in the concentration of these
molecules in blood, causing toxicity for the patient, especially
when antineoplastic drugs are used [24-26].
Conclusion
It is important to note that the metabolism of a xenobiotic is
carried out in most cases by a set of enzymes of Phase I and II
of the metabolism and not individually, so it is necessary to
study the combination of different allelic versions. The
information generated from the study of these polymorphisms
is relevant since it allows us to know the frequencies of these
variations in a population, clarify their influence on health and
monitor environmental risk or drugs to which an individual or
a population may be exposed. This allows the promotion of
pharmacogenetic studies that impact personalized treatment.
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